Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$51.26M

FY 2025 · Annual

Investing Cash Flow

$72.55M

FY 2025 · Annual

+79.2% YoY

Financing Cash Flow

-$1.15M

FY 2025 · Annual

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
Deferred Income Tax2K002K2K
Stock-Based Compensation4.09M5.09M5.21M4.11M4.42M
Change in Working Capital(34.67M)(6.01M)(6.01M)(3.8M)1.16M
Accounts Receivables(23.37M)25.26M(933K)(347K)463.2K
Inventory21.72M(19.93M)000
Accounts Payables1.66M(5.34M)(812K)524K62.08K
Other Working Capital(34.67M)(6.01M)(4.27M)(3.97M)630.33K
Other Non-Cash Items848K(753K)1.36M(7.88M)2.67M
Operating Cash Flow(90.95M)118.57M(59.01M)(59.25M)(51.26M)
Capital Expenditures(1.31M)(1.42M)(575K)(723K)(714K)
Acquisitions (Net)374K0000
Purchases of Investments(88.88M)(299.42M)(277.83M)(240.05M)(66.28M)
Sales of Investments67.88M199.22M319.44M277.02M137.81M
Other Investing Activities(304K)494K3.83M4.22M1.73M
Investing Cash Flow(22.24M)(101.12M)44.64M40.49M72.55M
Debt Repayment(1.18M)(1.19M)(1.2M)(1.21M)(1.21M)
Common Stock Issued51.49M250K31K17.34M63K
Common Stock Repurchased0(631K)000
Dividends Paid00000
Other Financing Activities267K250K31K(1.7M)0
Financing Cash Flow50.58M(1.57M)(1.17M)14.43M(1.15M)
Effect of Forex Changes701K258K(5.1M)894K(1.36M)
Net Change in Cash(61.91M)16.13M(20.64M)(3.44M)18.78M
Free Cash Flow(92.26M)117.15M(59.81M)(59.97M)(51.97M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$61.7M
+ D&A$2.1M
+ Stock-Based Comp$4.4M
+ Deferred Tax$2.0K
+ Working Capital$1.2M
+ Other Non-Cash$2.7M
= Operating Cash Flow-$51.3M
- Capex-$714.0K
= Free Cash Flow-$52.0M

Analysis

FY2025 free cash flow is -$52.0M. FCF conversion is 84.3% of net income. Operating cash flow was -$51.3M, with capex of -$714.0K. The largest bridge item is Stock-Based Comp at $4.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingOct 29, 2026
6-K6-K filingAug 25, 2026
6-K6-K filingJul 20, 2026
6-K6-K filingJul 7, 2026
6-K6-K filingJul 2, 2026

Does MOLN generate free cash flow?

Molecular Partners AG (MOLN) generated -$51.97M of free cash flow in fiscal 2025.

How much operating cash flow does MOLN produce?

Operating cash flow was -$51.26M, before capital expenditures of $714,000.00.